查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1866352

藥物釋放型植入市場－2025-2030年預測

Drug Eluting Implants Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 148 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計到 2025 年，藥物釋放型植入市場規模將達到 75.61 億美元，到 2030 年將達到 101.33 億美元，複合年成長率為 6.03%。

由於藥物洗脫植入物能夠以可控的釋放速率將活性藥物成分（API）直接輸送到目標組織，從而提高療效並最大限度地減少副作用，預計全球藥物釋放型植入市場將迎來顯著成長。植入，尤其是藥物釋放型支架（DES），優於傳統的口服或腸外給藥方式，並正日益廣泛地應用於糖尿病、癌症、避孕、愛滋病預防、慢性疼痛、心臟病和中樞神經系統疾病的治療。關鍵成長要素包括慢性病盛行率的上升、全球人口老化、研發投入的增加。儘管高昂的研發成本為市場帶來了挑戰，但病患接受度的提高和技術的進步正為其帶來益處。

市場促進因素

糖尿病患者數量增加

全球糖尿病盛行率的快速成長是藥物釋放型植入市場的主要驅動力。這些植入因其在糖尿病管理中的癒合特性而日益普及，能夠提供標靶藥物輸送，從而改善患者的治療效果。國際糖尿病聯盟（IDF）預測，到2045年，20至79歲糖尿病患者人數預計將達到7.02億，與過去幾年相比顯著成長。患者群體的成長預計將推動對藥物釋放型植入的需求不斷成長，其精準的藥物輸送機制有助於有效控制疾病，並將在2030年前推動市場擴張。

癌症發生率增加

全球癌症發生率的不斷攀升顯著擴大了藥物釋放型植入的市場，尤其是在化療領域。這些植入提供了一種微創且影像引導的給藥途徑，從而提高了治療的精確度。癌症病例的增加導致全球化療療程的增加，進一步印證了這類植入的需求。它們能夠在最大限度減少對健康組織損傷的同時，精準輸送標靶治療，使其成為腫瘤治療領域的重要工具，並將在預測期內進一步推動市場成長。

人口老化

根據聯合國估計，到2050年，全球老年人口預計將加倍，達到15億，這將成為推動市場成長的主要因素。隨著老年人更容易患上需要藥物釋放型植入的疾病，例如心血管疾病和癌症，市場需求將會增加。這種人口結構變化正在推動對先進治療方法的需求，使藥物釋放型植入成為與老齡化相關的健康挑戰的關鍵解決方案。

區域展望

由於人口老化加劇以及糖尿病和癌症發病率上升，亞太地區預計將迎來顯著的市場成長。儘管北美和歐洲憑藉其高普及率和先進的醫療基礎設施將繼續主導，但亞太地區醫療技術的快速發展和龐大的患者群體將鞏固其在2030年前作為高成長地區的地位。

競爭格局

包括iVascular、ProMed Pharma, LLC、強生公司、波士頓科學公司、默克集團、美敦力公司、Biosensors International Group、雅培公司、Elixir Medical Corporation和西門子醫療在內的主要企業正透過策略夥伴關係和產品研發推動創新。例如，2023年5月，iVascular的iCover球囊擴張型覆膜支架獲得CE核准，拓展了血管治療的選擇範圍。

市場展望

受慢性病盛行率上升、人口老化以及研發進步的推動，藥物釋放型植入市場預計到2030年將保持強勁成長。北美和歐洲市場的主導地位，以及亞太地區的快速擴張，凸顯了該市場的全球潛力。相關人員必須專注於創新和擴充性，以滿足不斷成長的需求，同時應對成本方面的挑戰。

本報告的主要優勢：

  • 深入分析：取得以客戶群、政府政策和社會經濟因素、消費者偏好、垂直產業和其他細分市場為重點的深入市場洞察，涵蓋主要地區和新興地區。
  • 競爭格局：了解主要企業採取的策略舉措，並了解透過正確的策略打入市場的潛力。
  • 市場促進因素與未來趨勢：探索動態因素和關鍵市場趨勢，以及它們將如何塑造未來的市場發展。
  • 可執行的建議：利用洞察力為策略決策提供訊息，從而在動態環境中開拓新的業務管道和收入來源。
  • 受眾範圍廣：對新興企業、研究機構、顧問公司、中小企業和大型企業都有益處且經濟高效。

它是用來做什麼的？

產業與市場洞察、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範及其影響、新產品開發、競爭影響

分析範圍

  • 歷史資料（2022-2024 年）和預測資料（2025-2030 年）
  • 成長機會、挑戰、供應鏈前景、法規結構、客戶行為和趨勢分析
  • 競爭對手定位、策略和市場佔有率分析
  • 按業務板塊和地區（國家）分類的收入成長和預測分析
  • 公司概況（策略、產品、財務資訊、關鍵趨勢等）

目錄

第1章執行摘要

第2章市場概述

  • 市場概覽
  • 市場定義
  • 分析範圍
  • 市場區隔

第3章 商業情境

  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 波特五力分析
  • 產業價值鏈分析
  • 政策和法規
  • 策略建議

第4章 技術展望

第5章 依產品類型藥物釋放型植入市場

  • 介紹
  • 藥物釋放型支架
  • 避孕植入
  • 藥物釋放型血管移植物
  • 其他

第6章 依材料分類的藥物釋放型植入市場

  • 介紹
  • 可生物分解
  • 不可生物分解

第7章 依應用分類的藥物釋放型植入市場

  • 介紹
  • 腫瘤學
  • 眼科
  • 心臟病學
  • 避孕和生育管理
  • 其他

第8章 依最終使用者分類的藥物釋放型植入市場

  • 介紹
  • 醫院
  • 門診手術中心
  • 其他

第9章 按地區分類的藥物釋放型植入市場

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 印尼
    • 泰國
    • 台灣
    • 其他

第10章 競爭格局與分析

  • 主要企業和策略分析
  • 市佔率分析
  • 企業合併、協議、商業合作
  • 競爭對手儀錶板

第11章 公司簡介

  • iVascular
  • ProMed Pharma
  • Boston Scientific Corporation
  • Merck Group
  • Medtronic, Inc.
  • Biosensors International Group
  • Abbott Laboratories
  • Elixir Medical Corporation
  • Biotronik SE & Co. KG
  • Lubrizol

第12章附錄

  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要收益
  • 分析方法
  • 簡稱
簡介目錄
Product Code: KSI061611191

The Drug Eluting Implants Market is forecasted to advance from USD 7.561 billion in 2025 to USD 10.133 billion by 2030, at a CAGR of 6.03%.

The global drug-eluting implants market is poised for significant growth, driven by their ability to deliver controlled-release active pharmaceutical ingredients (APIs) directly to targeted tissues, enhancing treatment efficacy while minimizing side effects. These implants, notably drug-eluting stents (DES), outperform traditional oral or parenteral drug delivery methods and are increasingly adopted for managing conditions such as diabetes, cancer, contraception, HIV/AIDS prevention, chronic pain, cardiology, and central nervous system disorders. Key growth drivers include the rising prevalence of chronic diseases, an aging global population, and increased R&D investments. The market faces challenges from high development costs but benefits from growing patient adoption and technological advancements.

Market Drivers

Rising Prevalence of Diabetes

The global surge in diabetes cases is a major catalyst for the drug-eluting implants market. These implants are increasingly utilized for their healing properties in diabetes management, offering targeted drug delivery to improve patient outcomes. The International Diabetes Federation projects that the number of people with diabetes aged 20-79 will reach 700,002 by 2045, up significantly from previous years. This growing patient population is expected to drive demand for drug-eluting implants, as their precise delivery mechanisms support effective disease management, fueling market expansion through 2030.

Increasing Cancer Incidence

The rising global incidence of cancer significantly boosts the market for drug-eluting implants, particularly in chemotherapy applications. These implants provide a minimally invasive, image-guided parenteral route for drug administration, enhancing treatment precision. The increasing number of chemotherapy sessions worldwide, driven by growing cancer cases, underscores the demand for such implants. Their ability to deliver targeted therapies with reduced impact on healthy tissues positions them as a critical tool in oncology, further accelerating market growth during the forecast period.

Aging Population

The global geriatric population, projected by the United Nations to double to 1.5 billion by 2050, is a key driver. Older individuals are more prone to conditions requiring drug-eluting implants, such as cardiovascular diseases and cancer, increasing market demand. This demographic shift amplifies the need for advanced treatment options, positioning drug-eluting implants as a vital solution in addressing age-related health challenges.

Geographical Outlook

The Asia-Pacific region is expected to experience significant market growth, driven by its expanding geriatric population and rising prevalence of diabetes and cancer. North America and Europe continue to lead due to high adoption rates and advanced healthcare infrastructure, but Asia-Pacific's rapid healthcare advancements and large patient base make it a high-growth region through 2030.

Competitive Landscape

Key players, including iVascular, ProMed Pharma, LLC, Johnson & Johnson, Boston Scientific Corporation, The Merck Group, Medtronic, Inc., Biosensors International Group, Abbott Laboratories, Elixir Medical Corporation, and Siemens Healthcare, are driving innovation through strategic partnerships and product development. For instance, in May 2023, iVascular received CE mark approval for its iCover balloon-expandable covered stent, enhancing vascular treatment options.

Market Outlook

The drug-eluting implants market is set for robust growth through 2030, propelled by rising chronic disease prevalence, an aging population, and R&D advancements. Asia-Pacific's rapid expansion, alongside North America and Europe's dominance, underscores the market's global potential. Stakeholders must focus on innovation and scalability to meet growing demand while addressing cost-related challenges.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Market Segmentation:

By Product Type

  • Drug Eluting Stents
  • Contraceptive Implants
  • Drug Eluting Vascular Grafts
  • Others

By Material

  • Biodegradable
  • Non-Biodegradable

By Application

  • Oncology
  • Ophthalmology
  • Cardiology
  • Contraception/Birth Control
  • Others

By End-User

  • Hospital
  • Ambulatory Surgical Centers
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Taiwan
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. DRUG ELUTING IMPLANTS MARKET BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. Drug Eluting Stents
  • 5.3. Contraceptive Implants
  • 5.4. Drug Eluting Vascular Grafts
  • 5.5. Others

6. DRUG ELUTING IMPLANTS MARKET BY MATERIAL

  • 6.1. Introduction
  • 6.2. Biodegradable
  • 6.3. Non-Biodegradable

7. DRUG ELUTING IMPLANTS MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Oncology
  • 7.3. Opthalmology
  • 7.4. Cardiology
  • 7.5. Contraception/Birth Control
  • 7.6. Others

8. DRUG ELUTING IMPLANTS MARKET BY END-USER

  • 8.1. Introduction
  • 8.2. Hospital
  • 8.3. Ambulatory Surgical Centers
  • 8.4. Others

9. DRUG ELUTING IMPLANTS MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. USA
    • 9.2.2. Canada
    • 9.2.3. Mexico
  • 9.3. South America
    • 9.3.1. Brazil
    • 9.3.2. Argentina
    • 9.3.3. Others
  • 9.4. Europe
    • 9.4.1. Germany
    • 9.4.2. France
    • 9.4.3. United Kingdom
    • 9.4.4. Italy
    • 9.4.5. Spain
    • 9.4.6. Others
  • 9.5. Middle East and Africa
    • 9.5.1. Saudi Arabia
    • 9.5.2. UAE
    • 9.5.3. Israel
    • 9.5.4. Others
  • 9.6. Asia Pacific
    • 9.6.1. China
    • 9.6.2. India
    • 9.6.3. Japan
    • 9.6.4. South Korea
    • 9.6.5. Indonesia
    • 9.6.6. Thailand
    • 9.6.7. Taiwan
    • 9.6.8. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. iVascular
  • 11.2. ProMed Pharma
  • 11.3. Boston Scientific Corporation
  • 11.4. Merck Group
  • 11.5. Medtronic, Inc.
  • 11.6. Biosensors International Group
  • 11.7. Abbott Laboratories
  • 11.8. Elixir Medical Corporation
  • 11.9. Biotronik SE & Co. KG
  • 11.10. Lubrizol

12. APPENDIX

  • 12.1. Currency
  • 12.2. Assumptions
  • 12.3. Base and Forecast Years Timeline
  • 12.4. Key benefits for the stakeholders
  • 12.5. Research Methodology
  • 12.6. Abbreviations